This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Chronic neutrophilic leukemia: new science and new diagnostic criteria
Blood Cancer Journal Open Access 13 February 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vardiman JW, Bennett JM, Bain BJ, Brunning RD, Thiele J . Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues . International Agency for Research on Cancer: Lyon, France, 2008, pp 80–81.
Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G . Identification of risk factors in atypical chronic myeloid leukemia. Haematologica 2006; 91: 1566–1568.
Koldehoff M, Beelen DW, Trenschel R, Steckel NK, Peceny R, Ditschkowski M et al. Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant 2004; 34: 1047–1050.
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013; 368: 1781–1790.
Piazza R, Valletta S, Winkelman N, Redaelli S, Spinelli R, Pirola A et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45: 18–24.
Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson CA et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013; 27: 1870–1873.
Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander AR et al. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplant 2010; 45: 1404–1407.
Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D et al. Impact of JAK2 V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010; 116: 3572–3581.
Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, Jäkel N et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica 2013; 98: 722–728.
Kröger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F et al. JAK2 V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 2009; 113: 1866–1868.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Langabeer, S., McCarron, S., Haslam, K. et al. The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT. Bone Marrow Transplant 49, 843–844 (2014). https://doi.org/10.1038/bmt.2014.35
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2014.35
This article is cited by
-
Molecular response of CSF3R T618I harboring chronic neutrophilic leukemia after induction chemotherapy linked to cord blood transplantation
Annals of Hematology (2019)
-
Chronic neutrophilic leukemia: new science and new diagnostic criteria
Blood Cancer Journal (2018)
-
Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis
Clinical and Translational Oncology (2018)